Author:
Arnold D.,Fuchs C.S.,Tabernero J.,Ohtsu A.,Zhu A.X.,Garon E.B.,Mackey J.R.,Paz-Ares L.,Baron A.D.,Okusaka T.,Yoshino T.,Yoon H.H.,Das M.,Ferry D.,Zhang Y.,Lin Y.,Binder P.,Sashegyi A.,Chau I.
Reference57 articles.
1. Cyramza [package insert US]. Eli Lilly and Company, Indianapolis, IN. April 2015; https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125477s011lbl.pdf (11 September 2017, date last accessed).
2. Cyramza [summary of product characteristics & package insert EMA]. Eli Lilly and Company, Indianapolis, IN. May 2017;http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002829/WC500180724.pdf (11 September 2017, date last accessed).
3. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial;Fuchs;Lancet,2014
4. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial;Wilke;Lancet Oncol,2014
5. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial;Garon;Lancet,2014
Cited by
88 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献